Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an update.
Cinclus Pharma has sponsored a scientific conference abstract presented at the ISPOR Europe 2025 conference, highlighting the significant clinical and economic costs associated with treatment failures of proton pump inhibitors (PPIs) in severe erosive GERD. The abstract emphasizes the need for new therapies, as current PPI treatments result in high healthcare costs and reduced quality of life for patients. Cinclus Pharma’s linaprazan glurate shows promise as a cost-effective alternative, with Phase II studies demonstrating superior healing rates compared to existing treatments.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, is a next-generation potassium competitive acid blocker designed to provide enhanced healing and symptom relief for severe gastroesophageal reflux disease (GERD).
Average Trading Volume: 66,957
Technical Sentiment Signal: Hold
Current Market Cap: SEK811.6M
See more data about CINPHA stock on TipRanks’ Stock Analysis page.